{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:38:13Z","timestamp":1780666693830,"version":"3.54.1"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.intimp.2022.109445","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T23:12:13Z","timestamp":1668726733000},"page":"109445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"PB","title":["Tau immunotherapy in Alzheimer\u2019s disease and progressive supranuclear palsy"],"prefix":"10.1016","volume":"113","author":[{"given":"Nastaran","family":"Karimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feyza","family":"Bayram \u00c7atak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amene","family":"Saghazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0005","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1074\/mcp.R115.053330","article-title":"Neurodegeneration and Alzheimer\u2019s disease (AD). What Can Proteomics Tell Us About the Alzheimer\u2019s Brain?","volume":"15","author":"Moya-Alvarado","year":"2016","journal-title":"Mol. Cell. Proteomics"},{"issue":"10","key":"10.1016\/j.intimp.2022.109445_b0010","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/gps.2655","article-title":"Personality changes in Alzheimer\u2019s disease: a systematic review","volume":"26","author":"Robins Wahlin","year":"2011","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","article-title":"Amyloid precursor protein processing and Alzheimer\u2019s disease","volume":"34","author":"O'Brien","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.intimp.2022.109445_b0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neulet.2019.04.022","article-title":"The complexity of tau in Alzheimer\u2019s disease","volume":"705","author":"Naseri","year":"2019","journal-title":"Neurosci. Lett."},{"issue":"6","key":"10.1016\/j.intimp.2022.109445_b0025","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/0896-6273(93)90057-X","article-title":"Abnormal tau phosphorylation at Ser396 in Alzheimer\u2019s disease recapitulates development and contributes to reduced microtubule binding","volume":"10","author":"Bramblett","year":"1993","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.intimp.2022.109445_b0030","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1016\/S0021-9258(17)42989-9","article-title":"Phosphorylation affects the ability of tau protein to promote microtubule assembly","volume":"259","author":"Lindwall","year":"1984","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.18388\/abp.2004_3617","article-title":"Genetic study of familial cases of Alzheimer\u2019s disease","volume":"51","author":"Kowalska","year":"2004","journal-title":"Acta Biochim. Pol."},{"issue":"5123","key":"10.1016\/j.intimp.2022.109445_b0040","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ana.10636","article-title":"Apolipoprotein Eepsilon4 modifies Alzheimer\u2019s disease onset in an E280A PS1 kindred","volume":"54","author":"Pastor","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.intimp.2022.109445_b0050","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/CIA.S105769","article-title":"Genes associated with Alzheimer\u2019s disease: an overview and current status","volume":"11","author":"Giri","year":"2016","journal-title":"Clin. Interv. Aging"},{"issue":"3","key":"10.1016\/j.intimp.2022.109445_b0055","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5582\/ddt.2021.01061","article-title":"Aducanumab: the first targeted Alzheimer\u2019s therapy","volume":"15","author":"Yang","year":"2021","journal-title":"Drug Discov Ther"},{"issue":"9634","key":"10.1016\/j.intimp.2022.109445_b0060","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00002512-200724020-00003","article-title":"Vaccination strategies for Alzheimer\u2019s disease: a new hope?","volume":"24","author":"Woodhouse","year":"2007","journal-title":"Drugs Aging"},{"issue":"10","key":"10.1016\/j.intimp.2022.109445_b0070","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1517\/14712598.2014.935332","article-title":"Amyloid-directed monoclonal antibodies for the treatment of Alzheimer\u2019s disease: the point of no return?","volume":"14","author":"Panza","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1586\/eci.11.93","article-title":"Solanezumab for the treatment of mild-to-moderate Alzheimer\u2019s disease","volume":"8","author":"Imbimbo","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00401-009-0486-3","article-title":"Mechanisms of tau-induced neurodegeneration","volume":"118","author":"Iqbal","year":"2009","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2217\/imt.11.170","article-title":"Immunotherapy for Alzheimer\u2019s disease: from anti-beta-amyloid to tau-based immunization strategies","volume":"4","author":"Panza","year":"2012","journal-title":"Immunotherapy"},{"issue":"7","key":"10.1016\/j.intimp.2022.109445_b0090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"Boxer","year":"2017","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109445_b0095","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ane.12546","article-title":"Progressive supranuclear palsy (PSP): richardson syndrome and other PSP variants","volume":"134","author":"Lopez","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.intimp.2022.109445_b0100","first-page":"355","article-title":"Tauopathies","volume":"145","author":"Kovacs","year":"2017","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.intimp.2022.109445_b0105","doi-asserted-by":"crossref","unstructured":"G.U. Hoglinger, G. Respondek, M. Stamelou, C. Kurz, K.A. Josephs, A.E. Lang, B. Mollenhauer, U. Muller, C. Nilsson, J.L. Whitwell, T. Arzberger, E. Englund, E. Gelpi, A. Giese, D.J. Irwin, W.G. Meissner, A. Pantelyat, A. Rajput, J.C. van Swieten, C. Troakes, A. Antonini, K.P. Bhatia, Y. Bordelon, Y. Compta, J.C. Corvol, C. Colosimo, D.W. Dickson, R. Dodel, L. Ferguson, M. Grossman, J. Kassubek, F. Krismer, J. Levin, S. Lorenzl, H.R. Morris, P. Nestor, W.H. Oertel, W. Poewe, G. Rabinovici, J.B. Rowe, G.D. Schellenberg, K. Seppi, T. van Eimeren, G.K. Wenning, A.L. Boxer, L.I. Golbe, I. Litvan, P.S.P.S.G. Movement Disorder Society-endorsed, Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria, Mov Disord 32(6) (2017) 853-864.","DOI":"10.1002\/mds.26987"},{"issue":"7","key":"10.1016\/j.intimp.2022.109445_b0110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ng.859","article-title":"Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy","volume":"43","author":"H\u00f6glinger","year":"2011","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.intimp.2022.109445_b0115","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00018-019-03349-1","article-title":"Mechanisms of secretion and spreading of pathological tau protein","volume":"77","author":"Brunello","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.intimp.2022.109445_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.569818","article-title":"The Cell Biology of Tau Secretion","volume":"13","author":"Merezhko","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"3","key":"10.1016\/j.intimp.2022.109445_b0125","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.neuron.2011.04.009","article-title":"The many faces of tau","volume":"70","author":"Morris","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.intimp.2022.109445_b0130","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fnagi.2016.00262","article-title":"Tau Structures","volume":"8","author":"Avila","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.intimp.2022.109445_b0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pneurobio.2018.12.005","article-title":"It's all about tau","volume":"175","author":"Tapia-Rojas","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.intimp.2022.109445_b0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/B978-0-12-385883-2.00004-7","article-title":"Tau and tauopathies","volume":"107","author":"Lee","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0145","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1152\/physrev.00024.2003","article-title":"Role of tau protein in both physiological and pathological conditions","volume":"84","author":"Avila","year":"2004","journal-title":"Physiol. Rev."},{"issue":"7","key":"10.1016\/j.intimp.2022.109445_b0150","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.intimp.2022.109445_b0155","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fnagi.2019.00204","article-title":"Role of Tau as a microtubule-associated protein: structural and functional aspects","volume":"11","author":"Barbier","year":"2019","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"10.1016\/j.intimp.2022.109445_b0160","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3233\/JAD-130653","article-title":"Tauopathies and tau oligomers","volume":"37","author":"Takashima","year":"2013","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.intimp.2022.109445_b0165","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3233\/JAD-150238","article-title":"Alzheimer\u2019s disease cerebrospinal fluid and neuroimaging biomarkers: diagnostic accuracy and relationship to drug efficacy","volume":"46","author":"Khan","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2022.109445_b0170","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/21678421.2014.971812","article-title":"Csf p-tau181\/tau ratio as biomarker for TDP pathology in frontotemporal dementia","volume":"16","author":"Borroni","year":"2015","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/JAD-2011-101641","article-title":"Human platelets tau: a potential peripheral marker for Alzheimer\u2019s disease","volume":"25","author":"Neumann","year":"2011","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.intimp.2022.109445_b0180","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3233\/JAD-140756","article-title":"Circulating miRNAs as potential biomarkers in Alzheimer\u2019s disease","volume":"42","author":"Galimberti","year":"2014","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00401-013-1193-7","article-title":"Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration","volume":"127","author":"Kouri","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109445_b0190","doi-asserted-by":"crossref","first-page":"530","DOI":"10.15252\/embr.201541438","article-title":"Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice","volume":"17","author":"Maeda","year":"2016","journal-title":"EMBO Rep."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2022.109445_b0195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000440840","article-title":"Genetic Disorders with Tau Pathology: a review of the literature and report of two patients with tauopathy and positive family histories","volume":"16","author":"Tacik","year":"2016","journal-title":"Neurodegener. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nan.12208","article-title":"Invited review: Neuropathology of tauopathies: principles and practice","volume":"41","author":"Kovacs","year":"2015","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109445_b0205","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1567205014666170417111859","article-title":"Tau in Alzheimer\u2019s Disease: Mechanisms and Therapeutic Strategies","volume":"15","author":"Gao","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.intimp.2022.109445_b0210","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neuropharm.2016.01.028","article-title":"TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice","volume":"105","author":"Jiang","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00401-021-02301-7","article-title":"Tau strains shape disease","volume":"142","author":"Vaquer-Alicea","year":"2021","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109445_b0220","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.neuron.2016.04.042","article-title":"Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model","volume":"90","author":"Schoch","year":"2016","journal-title":"Neuron."},{"issue":"3","key":"10.1016\/j.intimp.2022.109445_b0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: the therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol. Med."},{"issue":"24","key":"10.1016\/j.intimp.2022.109445_b0230","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1073\/pnas.1504081112","article-title":"Tau stabilizes microtubules by binding at the interface between tubulin heterodimers","volume":"112","author":"Kadavath","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13024-020-00391-7","article-title":"Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease","volume":"15","author":"Guo","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.intimp.2022.109445_b0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.sbi.2020.05.011","article-title":"Cryo-EM structures of tau filaments","volume":"64","author":"Scheres","year":"2020","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0245","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3233\/JAD-190155","article-title":"Phospho-Tau Protein Expression in the Cell Cycle of SH-SY5Y Neuroblastoma Cells: a Morphological Study","volume":"71","author":"Flores-Rodriguez","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.intimp.2022.109445_b0250","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3389\/fncel.2020.00247","article-title":"PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer's Disease","volume":"14","author":"Luna-Viramontes","year":"2020","journal-title":"Front. Cell. Neurosci."},{"issue":"4","key":"10.1016\/j.intimp.2022.109445_b0255","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/WCO.0000000000000836","article-title":"Immunotherapy in progressive supranuclear palsy","volume":"33","author":"Vaswani","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.intimp.2022.109445_b0260","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"issue":"Pt 10","key":"10.1016\/j.intimp.2022.109445_b0265","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/brain\/awu213","article-title":"Neuronal uptake of tau\/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer\u2019s disease","volume":"137","author":"Collin","year":"2014","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.intimp.2022.109445_b0270","doi-asserted-by":"crossref","first-page":"e0125614","DOI":"10.1371\/journal.pone.0125614","article-title":"Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models","volume":"10","author":"Sankaranarayanan","year":"2015","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0275","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40478-020-01003-7","article-title":"Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models","volume":"8","author":"Vitale","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13195-018-0341-7","article-title":"Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 x Tg-AD mice","volume":"10","author":"Dai","year":"2018","journal-title":"Alzheimers. Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0285","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13024-017-0229-1","article-title":"A validated antibody panel for the characterization of tau post-translational modifications","volume":"12","author":"Ercan","year":"2017","journal-title":"Mol. Neurodegener."},{"issue":"36","key":"10.1016\/j.intimp.2022.109445_b0290","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1523\/JNEUROSCI.1988-04.2004","article-title":"Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer\u2019s disease","volume":"24","author":"Horowitz","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.intimp.2022.109445_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.607303","article-title":"Neuronal and Glial Distribution of Tau Protein in the Adult Rat and Monkey","volume":"14","author":"Kanaan","year":"2021","journal-title":"Front. Mol. Neurosci."},{"issue":"3","key":"10.1016\/j.intimp.2022.109445_b0300","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","article-title":"Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial","volume":"20","author":"Hoglinger","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0305","doi-asserted-by":"crossref","first-page":"17034","DOI":"10.1038\/s41598-017-17313-1","article-title":"Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-beta Pathologies in 3xTg Mice","volume":"7","author":"Rajamohamedsait","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2022.109445_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104707","article-title":"Advances and considerations in AD tau-targeted immunotherapy","volume":"134","author":"Bittar","year":"2020","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2022.109445_b0315","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","article-title":"Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer\u2019s disease mouse models","volume":"142","author":"Ittner","year":"2010","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0320","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13195-018-0436-1","article-title":"FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer\u2019s disease","volume":"10","author":"Novak","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0325","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13024-020-00404-5","article-title":"Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer\u2019s disease","volume":"15","author":"Gibbons","year":"2020","journal-title":"Mol. Neurodegener."},{"issue":"49","key":"10.1016\/j.intimp.2022.109445_b0330","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1523\/JNEUROSCI.2016-16.2016","article-title":"Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice","volume":"36","author":"Liu","year":"2016","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.intimp.2022.109445_b0335","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1523\/JNEUROSCI.4989-14.2015","article-title":"Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer\u2019s disease mouse model","volume":"35","author":"Castillo-Carranza","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.intimp.2022.109445_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104636","article-title":"Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology","volume":"134","author":"Joly-Amado","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.intimp.2022.109445_b0345","unstructured":"Bio-nanoimaging, Academic Press, Boston."},{"issue":"6","key":"10.1016\/j.intimp.2022.109445_b0350","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.neuron.2010.11.030","article-title":"Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration","volume":"68","author":"Hoover","year":"2010","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.intimp.2022.109445_b0355","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimers Res. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0360","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109445_b0365","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat. Aging"},{"issue":"46","key":"10.1016\/j.intimp.2022.109445_b0370","doi-asserted-by":"crossref","first-page":"33081","DOI":"10.1074\/jbc.M113.494922","article-title":"Two novel Tau antibodies targeting the 396\/404 region are primarily taken up by neurons and reduce Tau protein pathology","volume":"288","author":"Gu","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.intimp.2022.109445_b0375","doi-asserted-by":"crossref","first-page":"13966","DOI":"10.1074\/jbc.M110.186338","article-title":"Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases","volume":"286","author":"Hickman","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.intimp.2022.109445_b0380","doi-asserted-by":"crossref","first-page":"e72301","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.109445_b0385","unstructured":"Active Tau Vaccine: Hints of Slowing Neurodegeneration. https:\/\/www.alzforum.org\/news\/conference-coverage\/active-TAU-vaccine-hints-slowing-neurodegeneration. (Accessed 17.04.2022)."},{"key":"10.1016\/j.intimp.2022.109445_b0390","unstructured":"AC Immune Advances Phospho-Tau Alzheimer\u2019s Vaccine In Phase 1b\/2a Study, Jul,16, 2020. https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-advances-phospho-tau-alzheimers-vaccine-phase-1b2a. (Accessed 14.04.2022)."},{"key":"10.1016\/j.intimp.2022.109445_b0395","unstructured":"AC Immune\u2019s Alzheimer\u2019s Vaccine Generates Potent Anti-PTau Antibody Response In A Phase 1b\/2a Study, Feb 11, 2021. https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immunes-alzheimers-vaccine-generates-potent-anti-ptau."},{"key":"10.1016\/j.intimp.2022.109445_b0400","unstructured":"THERAPEUTICS. https:\/\/www.alzforum.org\/therapeutics\/aci-35. (Accessed 17.04.2022)."},{"key":"10.1016\/j.intimp.2022.109445_b0405","unstructured":"AC Immune Announces Expansion Of Phase 1b\/2a Phospho-Tau Alzheimer\u2019s Vaccine Trial And Provides A Program Update, May 17, 2021. https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-announces-expansion-phase-1b2a-phospho-TAU-alzheimers. (Accessed 17.04.2022)."},{"issue":"8","key":"10.1016\/j.intimp.2022.109445_b0410","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease: a randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109445_b0415","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-021-01546-6","article-title":"Current status of clinical trials on tau immunotherapies","volume":"81","author":"Ji","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2022.109445_b0420","unstructured":"THERAPEUTICS. https:\/\/www.alzforum.org\/therapeutics\/gosuranemab. (Accessed 17.04.22)."},{"key":"10.1016\/j.intimp.2022.109445_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105120","article-title":"Characterization of tau binding by gosuranemab","volume":"146","author":"Sopko","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.intimp.2022.109445_b0430","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.trci.2018.10.007","article-title":"A randomized, single ascending dose study of intravenous BIIB092 in healthy participants","volume":"4","author":"Qureshi","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0435","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.neurobiolaging.2014.09.007","article-title":"Human secreted tau increases amyloid-beta production","volume":"36","author":"Bright","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0440","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00401-021-02318-y","article-title":"Tau immunotherapy is associated with glial responses in FTLD-tau","volume":"142","author":"Kim","year":"2021","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.intimp.2022.109445_b0445","doi-asserted-by":"crossref","unstructured":"T. Dam, A.L. Boxer, L.I. Golbe, G.U. Hoglinger, H.R. Morris, I. Litvan, A.E. Lang, J.C. Corvol, I. Aiba, M. Grundman, L. Yang, B. Tidemann-Miller, J. Kupferman, K. Harper, K. Kamisoglu, M.J. Wald, D.L. Graham, L. Gedney, J. O\u2019Gorman, S.B. Haeberlein, P.S. Group, Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial, Nat Med 27(8) (2021) 1451-1457.","DOI":"10.1038\/s41591-021-01455-x"},{"issue":"6","key":"10.1016\/j.intimp.2022.109445_b0450","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.intimp.2022.109445_b0455","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.trci.2018.09.005","article-title":"Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau","volume":"4","author":"Rosenqvist","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.intimp.2022.109445_b0460","doi-asserted-by":"crossref","unstructured":"J. Cummings, G. Lee, K. Zhong, J. Fonseca, K. Taghva, Alzheimer\u2019s disease drug development pipeline: 2021, Alzheimers Dement (N Y) 7(1) (2021) e12179.","DOI":"10.1002\/trc2.12179"},{"issue":"7S_Part_11","key":"10.1016\/j.intimp.2022.109445_b0465","doi-asserted-by":"crossref","first-page":"P592","DOI":"10.1016\/j.jalz.2017.07.227","article-title":"[O2\u201314\u201305]: PRE-Clinical characterization of an antibody [LY3303560] targeting aggregated tau","volume":"13","author":"Alam","year":"2017","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"39","key":"10.1016\/j.intimp.2022.109445_b0470","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","article-title":"Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression","volume":"286","author":"Chai","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2022.109445_b0475","doi-asserted-by":"crossref","unstructured":"K.G. Yiannopoulou, S.G. Papageorgiou, Current and Future Treatments in Alzheimer Disease: An Update, J Cent Nerv Syst Dis 12 (2020) 1179573520907397.","DOI":"10.1177\/1179573520907397"},{"key":"10.1016\/j.intimp.2022.109445_b0480","unstructured":"THERAPEUTICS JNJ-63733657. https:\/\/www.alzforum.org\/therapeutics\/jnj-63733657. (Accessed 17.04.2022)."},{"key":"10.1016\/j.intimp.2022.109445_b0485","doi-asserted-by":"crossref","unstructured":"W.R. Galpern, M. Mercken, K. Van Kolen, M. Timmers, K. Haeverans, L. Janssens, G. Triana-Baltzer, H.C. Kolb, T. Jacobs, P. Nandy, T. Malia, H. Sun, L. Van Nueten, P1-052: A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE ANTI-PHOSPHO-TAU ANTIBODY JNJ-63733657 IN HEALTHY SUBJECTS, Alzheimer\u2019s & Dementia 15(7S_Part_5) (2019) P252-P253.","DOI":"10.1016\/j.jalz.2019.06.077"},{"key":"10.1016\/j.intimp.2022.109445_b0490","unstructured":"UCB presents UCB0107 anti-Tau immunotherapy Phase I study results at World Movement Disorders Conference. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-presents-UCB0107-anti-TAU-immunotherapy-Phase-I-study-results-at-World-Movement-Disorders-Conference. (Accessed 17.04.2022)."},{"key":"10.1016\/j.intimp.2022.109445_b0495","unstructured":"Treating Tau: Finally, Clinical Candidates Are Stepping into the Ring, 27 Apr 2017. https:\/\/www.alzforum.org\/news\/conference-coverage\/treating-tau-finally-clinical-candidates-are-stepping-ring. (Accessed 17.04.2022)."},{"key":"10.1016\/j.intimp.2022.109445_b0500","unstructured":"THERAPEUTICS Tilavonemab. https:\/\/www.alzforum.org\/therapeutics\/tilavonemab. (Accessed 17.04.2022)."},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0505","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","article-title":"Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer\u2019s disease","volume":"8","author":"Roberts","year":"2020","journal-title":"Acta. Neuropathol. Commun."},{"key":"10.1016\/j.intimp.2022.109445_b0510","unstructured":"THERAPEUTICS BIIB076. https:\/\/www.alzforum.org\/therapeutics\/biib076. (Accessed 17.04.2022)."},{"key":"10.1016\/j.intimp.2022.109445_b0515","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.parkreldis.2021.10.007","article-title":"Development of a cognitive composite for measuring change in progressive supranuclear palsy","volume":"92","author":"Jaeger","year":"2021","journal-title":"Parkinsonism. Relat Disord"},{"issue":"4","key":"10.1016\/j.intimp.2022.109445_b0520","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1756285611404470","article-title":"Disease-modifying treatments for Alzheimer\u2019s disease","volume":"4","author":"Galimberti","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.intimp.2022.109445_b0525","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.conb.2018.04.027","article-title":"Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease","volume":"51","author":"Tracy","year":"2018","journal-title":"Curr. Opin. Neurobiol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0530","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuron.2018.06.003","article-title":"Dendritic Tau in Alzheimer\u2019s Disease","volume":"99","author":"Ittner","year":"2018","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.intimp.2022.109445_b0535","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1074\/mcp.M900578-MCP200","article-title":"Quantitative measurement of in vivo phosphorylation states of Cdk5 activator p35 by Phos-tag SDS-PAGE","volume":"9","author":"Hosokawa","year":"2010","journal-title":"Mol. Cell. Proteomics"},{"issue":"8","key":"10.1016\/j.intimp.2022.109445_b0540","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1567205016666190913155950","article-title":"A pilot study of exenatide actions in alzheimer\u2019s disease","volume":"16","author":"Mullins","year":"2019","journal-title":"Curr. Alzheimer Res."},{"issue":"5","key":"10.1016\/j.intimp.2022.109445_b0545","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1192\/bjp.bp.110.080044","article-title":"Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial","volume":"198","author":"Forlenza","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.intimp.2022.109445_b0550","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.parkreldis.2020.04.014","article-title":"Progressive supranuclear palsy: advances in diagnosis and management","volume":"73","author":"Coughlin","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.intimp.2022.109445_b0555","doi-asserted-by":"crossref","unstructured":"S. Lovestone, M. Boada, B. Dubois, M. Hull, J.O. Rinne, H.J. Huppertz, M. Calero, M.V. Andres, B. Gomez-Carrillo, T. Leon, T. del Ser, A. investigators, A phase II trial of tideglusib in Alzheimer\u2019s disease, J Alzheimers Dis 45(1) (2015) 75-88.","DOI":"10.3233\/JAD-141959"},{"issue":"4","key":"10.1016\/j.intimp.2022.109445_b0560","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"Tolosa","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.intimp.2022.109445_b0565","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2051-5960-2-22","article-title":"MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer\u2019s disease granulovacuolar degeneration bodies","volume":"2","author":"Lund","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"issue":"11","key":"10.1016\/j.intimp.2022.109445_b0570","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1523\/JNEUROSCI.4922-11.2012","article-title":"The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice","volume":"32","author":"Zhang","year":"2012","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0575","first-page":"215","article-title":"Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in patients with alzheimer disease","volume":"77","author":"Tsai","year":"2020","journal-title":"Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clin. Trial, JAMA Neurol"},{"issue":"18","key":"10.1016\/j.intimp.2022.109445_b0580","doi-asserted-by":"crossref","first-page":"16504","DOI":"10.1074\/jbc.M110.208447","article-title":"Alternative mitochondrial electron transfer as a novel strategy for neuroprotection","volume":"286","author":"Wen","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2022.109445_b0585","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00213-008-1394-2","article-title":"Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine","volume":"202","author":"Deiana","year":"2009","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0590","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2022.109445_b0595","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01689233. (Accessed 17.04.2022)."},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0600","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"10062","key":"10.1016\/j.intimp.2022.109445_b0605","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0610","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for treatment of mild alzheimer\u2019s disease: cohort analysis as modified primary outcome in a phase III Clinical Trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.intimp.2022.109445_b0615","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3233\/JAD-190772","article-title":"Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer\u2019s Disease","volume":"72","author":"Schelter","year":"2019","journal-title":"J. Alzheimers Dis."},{"issue":"20","key":"10.1016\/j.intimp.2022.109445_b0620","doi-asserted-by":"crossref","first-page":"23328","DOI":"10.1021\/acsami.1c00257","article-title":"Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer\u2019s Disease","volume":"13","author":"Zhu","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.intimp.2022.109445_b0625","doi-asserted-by":"crossref","unstructured":"G. Han, K. Bai, X. Yang, C. Sun, Y. Ji, J. Zhou, H. Zhang, Y. Ding, \u201cDrug-Carrier\u201d Synergy Therapy for Amyloid-beta Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly, Adv Sci (Weinh) 9(14) (2022) e2106072.","DOI":"10.1002\/advs.202106072"},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0630","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13024-019-0340-6","article-title":"Targeting tauopathy with engineered tau-degrading intrabodies","volume":"14","author":"Gallardo","year":"2019","journal-title":"Mol. Neurodegener"},{"issue":"2","key":"10.1016\/j.intimp.2022.109445_b0635","doi-asserted-by":"crossref","first-page":"308","DOI":"10.7150\/thno.17155","article-title":"Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor","volume":"7","author":"Hultqvist","year":"2017","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.intimp.2022.109445_b0640","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-020-0172-y","article-title":"Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice","volume":"5","author":"Takeuchi","year":"2020","journal-title":"npj Vaccines"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922009304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922009304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:43:03Z","timestamp":1761586983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922009304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":128,"alternative-id":["S1567576922009304"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109445","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tau immunotherapy in Alzheimer\u2019s disease and progressive supranuclear palsy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109445"}}